The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
|Articles|March 2, 2017
GEMÜ Valves
Advertisement
GEMÜ Valves is a leading world-wide manufacturer of valves, measurement, and control systems for the Pharmaceutical, Microelectronics, and Semiconductor, and Food and Beverage industries, as well as the Chemical, Mining, and Metal Extraction, and Water/Waste Water Treatment industries. GEMÜ is committed to the pursuit of quality and excellence in the development, production, and manufacturing of engineered diaphragm valves.
3800 Camp Creek Pkwy SW, Bldg 2600 Suite 120, Atlanta, GA 30331
info@gemu.com
tel. 678.553.3400
fax. 404.344.9350
INTERPHEX Booth #2663
Advertisement
Related to this article
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
3
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
4
NVIDIA’s $250M Agentic AI Safety Bet: What GMP Gains
5